Last $100.73 USD
Change Today +2.54 / 2.59%
Volume 929.6K
SLXP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 3:53 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (SLXP) Snapshot

Open
$101.96
Previous Close
$98.19
Day High
$102.05
Day Low
$97.99
52 Week High
02/28/14 - $120.00
52 Week Low
04/18/13 - $47.60
Market Cap
6.4B
Average Volume 10 Days
1.1M
EPS TTM
$2.19
Shares Outstanding
63.3M
EX-Date
--
P/E TM
45.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for SALIX PHARMACEUTICALS LTD (SLXP)

salix pharmaceuticals ltd (SLXP) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (SLXP) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (SLXP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $834.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $470.1K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $448.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $420.2K
Compensation as of Fiscal Year 2012.

salix pharmaceuticals ltd (SLXP) Key Developments

Furiex Puts Itself On The Block

Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) has reportedly hired Bank of America Corp to find a buyer. Bloomberg reported that Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP), Actavis plc (NYSE:ACT) and Takeda Pharmaceutical Company Limited (TSE:4502) to be potential buyers for Furiex. Tony Plohoros, representative for Furiex, declined to comment. G. Michael Freeman, spokesman for Salix, said the company had no comment when asked if it was considering an acquisition of Furiex. Representatives for Actavis and Takeda declined to comment when asked if they were considering an acquisition of Furiex.

Salix Pharmaceuticals, Ltd. Announces Unaudited Consolidated Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Full Year Ending December 31, 2014 and First Quarter Ending March 30, 2014

Salix Pharmaceuticals Ltd. announced unaudited consolidated results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, as compared to the fourth quarter of 2012, total product revenue increased 30% to $257.6 million from $198.173 million. EBITDA increased 50% to $101.9 million from $68.0 million a year ago. Non-GAAP net income for the fourth quarter of 2013 was $73.5 million, or $1.06 per diluted share, compared to $50.9 million, or $0.81 per diluted share, for the fourth quarter of 2012. GAAP net income was $52.3 million, or $0.76 per diluted share, in the fourth quarter of 2013 compared to $17.6 million, or $0.28 per diluted share, in the year ago period. Income from operations was $95.983 million against $46.899 million a year ago. Income before income tax was $81.272 million against $30.205 million a year ago. For the full year 2013, as compared to the full year 2012, total net product revenue increased 27% to $933.8 million from $735.444 million. EBITDA increased 37% to $352.5 million from $257.6 million a year ago. For the full year 2013, GAAP net income was $143.0 million, or $2.18 per diluted share, compared to $64.2 million, or $1.01 per diluted share, for the prior year. For the full year 2013, non-GAAP net income was $246.9 million, or $3.76 per diluted share, compared to $205.4 million, or $3.22 per diluted share, for the prior year. Income from operations was $271.713 million against $172.073 million a year ago. Income before income tax was $212.065 million against $111.828 million a year ago. For the full year ending December 31, 2014, the company expects total product revenue of approximately $1.6 billion. EBITDA, excluding expenses associated with the acquisition of Santarus, of approximately $650 million. Non-GAAP net income of approximately $475 million, or $6.46 per share, fully diluted. This assumes a cash income tax rate of approximately 12%. GAAP net income of $101.2 million. For the first quarter ending March 30, 2014, the company expects total product revenue of approximately $373 million. EBITDA, excluding expenses associated with the acquisition of Santarus, of approximately $130 million. Non-GAAP net income of approximately $61 million, or $0.85 per share, fully diluted. This assumes a cash income tax rate of approximately 40%. GAAP net loss of $22.5 million.

Salix Pharmaceuticals and Redhill Biopharma Announce Exclusive License Agreement for RedHill's RHB-106 Encapsulated Bowel Preparation

Salix Pharmaceuticals Ltd. announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. Financial terms of the transaction include an upfront payment of $7 million and $5 million in subsequent milestone payments to RedHill. Salix also has agreed to pay RedHill tiered royalties on net sales, ranging from low single-digit up to low double-digits. Under the worldwide license agreement, the parties also agreed on potential strategic collaboration with regard to certain other Salix products in specific territories. About RHB-106 RHB-106 is an encapsulated formulation intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures, including diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy. The RHB-106 preparation is a tasteless solid oral dosage potentially allowing an unobstructed procedure with reduced side-effects and improved compliance. It avoids patient exposure to the often unacceptable taste of current products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLXP:US $100.78 USD +2.59

SLXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €10.80 EUR -0.03
Cubist Pharmaceuticals Inc $64.06 USD +0.87
Jazz Pharmaceuticals Plc $136.80 USD +5.89
Recordati SpA €11.76 EUR -0.01
Santen Pharmaceutical Co Ltd ¥4,705 JPY +90.00
View Industry Companies
 

Industry Analysis

SLXP

Industry Average

Valuation SLXP Industry Range
Price/Earnings 45.1x
Price/Sales 6.6x
Price/Book 8.3x
Price/Cash Flow 33.1x
TEV/Sales 3.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.